A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects
Status:
Recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the pharmacokinetic characteristics and safety of
YHD1119(Pregabalin SR 75mg) and YHD1119(Pregabalin SR 150mg) in subjects with renal
impairment and healthy subjects. YHD1119 is sustained-release (SR) formulation which is made
by Yuhan Corporation. Primary endpoints are Cmax and AUClast and secondary endpoints are
AUCinf,Tmax, t1/2, CL/F and V/F.